Spinal injection trial seeks to slow Parkinson's progression
NCT ID NCT06565195
Summary
This early-stage study is testing the safety and behavior of a new drug, LY3962681, delivered by injection into the spinal fluid. It involves healthy volunteers receiving a single dose and Parkinson's disease patients receiving two doses. The main goal is to see how well the drug is tolerated and how it moves through the body over a year of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Clinic PPD
RECRUITINGAustin, Texas, 78744-1625, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ehime University Hospital
NOT_YET_RECRUITINGTōon, Ehime, 791-0295, Japan
-
Oita University Hospital
NOT_YET_RECRUITINGYufu, Oita Prefecture, 879-5593, Japan
-
P-One Clinic, Keikokai Medical Corporation
RECRUITINGHachiōji, Tokyo, 192-0071, Japan
Conditions
Explore the condition pages connected to this study.